


**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Cardiology Associates, LLC d/b/a MedStar Health Cardiology Associates</p> <p>2. 1133 21st Street, NW Suite 700 Washington, DC 20036</p>		<p>In accordance with letter dated March 26, 2020,</p>	<p>4. Expiration Date: March 31, 2022</p>
		<p>3. License No.: 08-23376-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-20994 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.200</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p>	<p>9. Authorized use</p> <p>A. For use in imaging and localization studies permitted by 10 CFR 35.200.</p>



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 08-23376-01

Docket or Reference No.:  
030-20994

Amendment No. 14  
(Corrected Copy)

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 1133 21st Street, NW, Suite 700, Washington, D.C. and 106 Irving Street, N.W., Suite 4800-N Washington, D.C.
11. The Radiation Safety Officer for this license is Oluseyi O. Princewill, M.D.
12. A. Individuals permitted to work as an authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User (M.D.,D.O.,etc.)</u> | <u>Material and Use</u> |
|---|-------------------------|
| Edward Ian Morris, M.D.                 | 10 CFR 35.200           |
| Oluseyi Princewill, M.D.                | 10 CFR 35.200           |
| Reginald Lamar Robinson, M.D.           | 10 CFR 35.200           |
13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 08-23376-01

Docket or Reference No.:  
030-20994Amendment No. 14  
(Corrected Copy)

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated September 15, 2011 [ML112720142]
- B. Letter (with attachments) dated February 15, 2012 [ML12080A183]
- C. Letter dated July 5, 2016 [ML16202A369]
- D. Letter received November 14, 2016 [ML16335A247]



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: February 10, 2021By: \_\_\_\_\_  
Robert Gallagher  
Region 1